Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

98P - Sarcomas with BCOR and CIC aberrations in children: Advanced diagnosis and treatment outcomes

Date

21 Mar 2025

Session

Poster Display session

Presenters

Kseniya Sinichenkova

Citation

Annals of Oncology (2025) 10 (suppl_3): 1-30. 10.1016/esmoop/esmoop104375

Authors

K. Sinichenkova1, A. Panferova2, I. Sidorov3, N. Grachev4, A. Druy5

Author affiliations

  • 1 Oncology And Hematology Of Young Adult Department, Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, 117198 - Москва/RU
  • 2 Laboratory Of Molecular Oncology, Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, 117997 - Moscow/RU
  • 3 Pathology Department, Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, 117997 - Moscow/RU
  • 4 Oncology And Pediatric Surgery Department, Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, 117997 - Moscow/RU
  • 5 Laboratory Of Molecular Oncology, Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, 117198 - Москва/RU

Resources

This content is available to ESMO members and event participants.

Abstract 98P

Background

The rare pediatric sarcoma with BCOR and CIC gene rearrangement show biological and clinical distinctions from other URCS. In this retrospective study we compare clinical features sarcoma with BCOR genetic alteration and CIC-rearranged sarcoma in children while assessing the utility of advanced diagnostic algorithms.

Methods

We analyzed of 42 URCS using reverse transcription PCR assay, RNA sequencing and Nanostring technology.

Results

Sarcoma with BCOR genetic alteration was diagnosed in 23 cases, including 17 cases of BCOR::CCNB3 (ex15::ex5), 2 cases of BCOR ITD (ex15), one cases of BCOR::MAML3 (ex15::ex2) and YWHAE::NUTM2B (ex5::ex2); in 2 cases based on gene expression profiles. Median age was 10.5 years (0.25-16.4), the f:m ratio was 1:10. Localized disease observed in 17 cases (74%), 6 cases (26%) had distant metastases. The primary lesion was localized intraosseously in 15 cases (65%), axial skeleton mostly (10 cases), and 8 in soft tissues (35%). 3-year OS and EFS were respectively 96.0±0.04% and 66.8±0.12% (p=0.01). There were no statistically significance differences in distribution of EFS depends on treatment protocols (EuroEwing or CWS) in patients with sarcoma with BCOR genetic alteration (p = 0.571). CIC-rearranged sarcoma was diagnosed in 14 cases: 5 cases of CIC::DUX4 (mostly ex21::ex1), 4 cases of CIC ex21, 2 cases of CIC::DUX4L9 (ex16::ex1 and ex21::ex1), 1 case of CIC::NUTM2B (ex20::intr4), in 2 cases was verified regards gene expression profiles. The median age at diagnosis was 14.4 years (1.76-16.6), the f:m ratio was 4:10. Distant metastasis observed in 8 cases (57%), 6 cases (43%) had localized decease. The primary lesion was localized in soft tissues (12 cases, 86%) or intraosseously (2 cases, 14%). 3-year OS and RFS in this group were respectively 34.4±16.0% and 23.8±14.6 (p=0.014).

Conclusions

NanoString technology demonstrate advantage in the extremely high levels of RNA degradation samples and difficult-to-detect CIC fusion transcripts. Sarcoma with BCOR genetic alteration demonstrates predominance in males, axial skeleton bones affinity, high rate of late relapse. CIC-rearranged sarcoma associated with an aggressive clinical course, high frequent of the distant metastases and fatal relapses.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

“Science for Children” foundation.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.